List of bibliographic references
Number of relevant bibliographic references: 6.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 2 | Adult |
| 2 | Breast Neoplasms (drug therapy) |
| 2 | Chemotherapy, Adjuvant |
| 2 | Female |
| 2 | Humans |
| 2 | Middle Aged |
| 2 | Receptor, ErbB-2 (metabolism) |
| 1 | Aged |
| 1 | Aminopyridines (administration & dosage) |
| 1 | Aminopyridines (adverse effects) |
| 1 | Antineoplastic Agents (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Australia |
| 1 | Biomarkers, Tumor (antagonists & inhibitors) |
| 1 | Biomarkers, Tumor (genetics) |
| 1 | Biomarkers, Tumor (metabolism) |
| 1 | Biopsy |
| 1 | Breast Neoplasms (enzymology) |
| 1 | Breast Neoplasms (metabolism) |
| 1 | Breast Neoplasms (pathology) |
| 1 | Carcinoma (drug therapy) |
| 1 | Carcinoma (metabolism) |
| 1 | Chemical and Drug Induced Liver Injury (etiology) |
| 1 | Class I Phosphatidylinositol 3-Kinases (antagonists & inhibitors) |
| 1 | Class I Phosphatidylinositol 3-Kinases (genetics) |
| 1 | Class I Phosphatidylinositol 3-Kinases (metabolism) |
| 1 | Disease-Free Survival |
| 1 | Double-Blind Method |
| 1 | Early Termination of Clinical Trials |
| 1 | Estrogen Receptor alpha (genetics) |
| 1 | Estrogen Receptor alpha (metabolism) |
| 1 | Europe |
| 1 | Immunohistochemistry |
| 1 | In Situ Hybridization, Fluorescence |
| 1 | Ki-67 Antigen (metabolism) |
| 1 | Lymphocytes, Tumor-Infiltrating (drug effects) |
| 1 | Morpholines (administration & dosage) |
| 1 | Morpholines (adverse effects) |
| 1 | Multivariate Analysis |
| 1 | Mutation |
| 1 | Neoadjuvant Therapy (adverse effects) |
| 1 | Paclitaxel (administration & dosage) |
| 1 | Paclitaxel (adverse effects) |
| 1 | Prognosis |
| 1 | Proportional Hazards Models |
| 1 | Protein Kinase Inhibitors (administration & dosage) |
| 1 | Protein Kinase Inhibitors (adverse effects) |
| 1 | RNA, Messenger (metabolism) |
| 1 | Randomized Controlled Trials as Topic |
| 1 | Receptor, ErbB-2 (antagonists & inhibitors) |
| 1 | Receptor, ErbB-2 (genetics) |
| 1 | Time Factors |
| 1 | Trastuzumab (administration & dosage) |
| 1 | Trastuzumab (adverse effects) |
| 1 | Trastuzumab (therapeutic use) |
| 1 | Treatment Outcome |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Sherene Loi"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Sherene Loi" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Sherene Loi
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
